Receiveable Turnover: An accounting measure used to quantify a firm's effectiveness in extending credit as well as collecting debts. Calculated as: Total Revenues / Accounts Receivable
Tarsus Pharmaceuticals, Inc. (TARS) had Receiveable Turnover of 1.38 for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
$162.05M |
|
$-6.97M |
|
$9.40M |
|
$152.66M |
|
$168.18M |
|
$-6.12M |
|
$1.51M |
|
$0.00M |
|
$-4.62M |
|
$-6.97M |
|
$-6.97M |
|
$-6.97M |
|
$-6.97M |
|
$-6.12M |
|
$-6.38M |
|
42.96M |
|
42.96M |
|
$-0.16 |
|
$-0.16 |
|
| Balance Sheet Financials | |
$537.23M |
|
$17.67M |
|
$43.91M |
|
$581.13M |
|
$143.51M |
|
$72.60M |
|
$88.68M |
|
$232.18M |
|
$348.95M |
|
$341.82M |
|
$348.95M |
|
43.02M |
|
| Cash Flow Statement Financials | |
$-24.65M |
|
$-58.56M |
|
$1.20M |
|
$186.20M |
|
$104.19M |
|
$-82.01M |
|
$11.97M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.74 |
|
-- |
|
-- |
|
0.17 |
|
0.21 |
|
94.20% |
|
-3.78% |
|
-3.78% |
|
-- |
|
-- |
|
-4.30% |
|
$-30.47M |
|
-- |
|
-- |
|
-- |
|
0.28 |
|
2.06 |
|
|
Receiveable Turnover |
1.38 |
65.09 |
|
-2.00% |
|
-2.04% |
|
-1.20% |
|
-1.65% |
|
$8.11 |
|
$-0.71 |
|
$-0.57 |
|